Document And Entity Information
Document And Entity Information - USD ($) | 12 Months Ended | ||
Dec. 31, 2016 | Mar. 30, 2017 | Jun. 30, 2016 | |
Document Information [Line Items] | |||
Entity Registrant Name | BIOLARGO, INC. | ||
Entity Central Index Key | 880,242 | ||
Trading Symbol | blgo | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Filer Category | Smaller Reporting Company | ||
Entity Current Reporting Status | Yes | ||
Entity Voluntary Filers | No | ||
Entity Well-known Seasoned Issuer | No | ||
Entity Common Stock, Shares Outstanding (in shares) | 94,945,211 | ||
Entity Public Float | $ 23,993,345 | ||
Document Type | 10-K | ||
Document Period End Date | Dec. 31, 2016 | ||
Document Fiscal Year Focus | 2,016 | ||
Document Fiscal Period Focus | FY | ||
Amendment Flag | false |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) | Dec. 31, 2016 | Dec. 31, 2015 |
Current assets: | ||
Cash and cash equivalents | $ 1,910,153 | $ 1,763,114 |
Accounts receivable | 67,994 | 41,431 |
Inventories | 34,446 | 37,435 |
Prepaid expenses and other current assets | 4,089 | 49,167 |
Total current assets | 2,016,682 | 1,891,147 |
Equipment, net of depreciation | 59,315 | |
Other non-current assets, net of amortization | 36,729 | 19,157 |
Total assets | 2,112,726 | 1,910,304 |
Current liabilities: | ||
Accounts payable and accrued expenses | 200,103 | 324,983 |
Officer bonus | 80,000 | |
Convertible notes payable | 560,000 | |
Discount on convertible notes payable, net of amortization | (398,910) | |
Derivative warrant liability | 663,560 | |
Line of credit | 50,000 | |
Deposits | 135,000 | |
Total current liabilities | 1,154,753 | 459,983 |
Long-term liabilities: | ||
Convertible notes payable | 5,250,668 | 3,245,972 |
Discount on convertible notes payable and line of credit, net of amortization | (3,522,497) | (2,937,019) |
Total liabilities | 2,882,924 | 768,936 |
COMMITMENTS, CONTINGENCIES (Note 9) | ||
STOCKHOLDERS’ EQUITY (DEFICIT): | ||
Preferred Series A, $.00067 Par Value, 50,000,000 Shares Authorized, -0- Shares Issued and Outstanding, at December 31, 2015 and December 31, 2016, respectively. | 0 | 0 |
Common stock, $.00067 Par Value, 200,000,000 Shares Authorized, 85,648,015 and 92,975,970 Shares Issued, at December 31, 2015 and December 31, 2016, respectively. | 62,179 | 57,236 |
Additional paid-in capital | 90,609,774 | 84,410,821 |
Accumulated other comprehensive loss | (81,694) | (40,567) |
Accumulated deficit | (91,915,426) | (84,075,695) |
Total Biolargo Inc. and Subsidiaries stockholders’ equity (deficit) | (1,325,167) | 351,795 |
Non-controlling interest (Note 8) | 554,969 | 789,573 |
Total stockholders’ equity (deficit) | (770,198) | 1,141,368 |
Total liabilities and stockholders’ equity | $ 2,112,726 | $ 1,910,304 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parentheticals) - $ / shares | Dec. 31, 2016 | Dec. 31, 2015 |
Preferred stock, par value (in dollars per share) | $ 0.00067 | $ 0.00067 |
Preferred stock, shares authorized (in shares) | 50,000,000 | 50,000,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares outstanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.00067 | $ 0.00067 |
Common stock, shares authorized (in shares) | 200,000,000 | 200,000,000 |
Common stock, shares issued (in shares) | 92,975,970 | 85,648,015 |
Consolidated Statements of Oper
Consolidated Statements of Operations - USD ($) | 12 Months Ended | |
Dec. 31, 2016 | Dec. 31, 2015 | |
Revenue | ||
Product revenue | $ 226,106 | $ 127,582 |
License revenue | 55,000 | |
Total revenue | 281,106 | 127,582 |
Cost of revenue | (105,877) | (62,067) |
Gross profit | 175,229 | 65,515 |
Selling, general and administrative expenses | 3,714,398 | 3,551,522 |
Research and development | 1,381,956 | 684,554 |
Depreciation and amortization | 13,736 | 10,920 |
Operating loss | (4,934,861) | (4,181,481) |
Other (expense) income: | ||
Grant income | 161,430 | 99,122 |
Interest expense | (3,129,104) | (994,671) |
Change in derivative liability | (171,800) | |
Total Other (expense) income | (3,139,474) | (895,549) |
Net loss | (8,074,335) | (5,077,030) |
Net loss attributable to noncontrolling interest | (234,604) | (21,054) |
Net loss attributable to common stockholders | $ (7,839,731) | $ (5,055,976) |
Loss per share attributable to stockholders – basic and diluted (in dollars per share) | $ (0.09) | $ (0.06) |
Weighted average number of common shares outstanding: (in shares) | 87,936,783 | 84,112,356 |
Foreign translation adjustment | $ (41,127) | $ (40,567) |
Comprehensive loss | (8,115,462) | (5,117,597) |
Comprehensive loss attributable to noncontrolling interest | (234,604) | (21,054) |
Comprehensive loss attributable to stockholders | $ (7,880,858) | $ (5,096,543) |
Consolidated Statement of Stock
Consolidated Statement of Stockholders' Equity (Deficit) - USD ($) | Vendors and Note Holders [Member]Common Stock [Member] | Vendors and Note Holders [Member]Additional Paid-in Capital [Member] | Vendors and Note Holders [Member]Retained Earnings [Member] | Vendors and Note Holders [Member]AOCI Attributable to Parent [Member] | Vendors and Note Holders [Member]Noncontrolling Interest [Member] | Vendors and Note Holders [Member] | Vendors and Officers [Member]Common Stock [Member] | Vendors and Officers [Member]Additional Paid-in Capital [Member] | Vendors and Officers [Member]Retained Earnings [Member] | Vendors and Officers [Member]AOCI Attributable to Parent [Member] | Vendors and Officers [Member]Noncontrolling Interest [Member] | Vendors and Officers [Member] | Warrants Issued in Conjunction with Convertible Notes and Letter of Credit [Member]Common Stock [Member] | Warrants Issued in Conjunction with Convertible Notes and Letter of Credit [Member]Additional Paid-in Capital [Member] | Warrants Issued in Conjunction with Convertible Notes and Letter of Credit [Member]Retained Earnings [Member] | Warrants Issued in Conjunction with Convertible Notes and Letter of Credit [Member]AOCI Attributable to Parent [Member] | Warrants Issued in Conjunction with Convertible Notes and Letter of Credit [Member]Noncontrolling Interest [Member] | Warrants Issued in Conjunction with Convertible Notes and Letter of Credit [Member] | Warrants Issued for Financing Fees [Member]Common Stock [Member] | Warrants Issued for Financing Fees [Member]Additional Paid-in Capital [Member] | Warrants Issued for Financing Fees [Member]Retained Earnings [Member] | Warrants Issued for Financing Fees [Member]AOCI Attributable to Parent [Member] | Warrants Issued for Financing Fees [Member]Noncontrolling Interest [Member] | Warrants Issued for Financing Fees [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | AOCI Attributable to Parent [Member] | Noncontrolling Interest [Member] | Total |
Balance (in shares) at Dec. 31, 2014 | 82,909,300 | |||||||||||||||||||||||||||||
Balance at Dec. 31, 2014 | $ 55,293 | $ 78,511,529 | $ (79,019,719) | $ 60,627 | $ (392,270) | |||||||||||||||||||||||||
Issuance of stock in exchange for Clyra shares (in shares) | 1,640,000 | |||||||||||||||||||||||||||||
Issuance of stock in exchange for Clyra shares | $ 1,099 | (1,099) | ||||||||||||||||||||||||||||
Conversion of equity to notes payable (in shares) | (530,000) | |||||||||||||||||||||||||||||
Conversion of equity to notes payable | $ (355) | (211,662) | (212,017) | |||||||||||||||||||||||||||
Issuance of common stock to vendors and interest to note holders (in shares) | 631,643 | 738,837 | ||||||||||||||||||||||||||||
Issuance of common stock to vendors and interest to note holders | $ 530 | $ 359,834 | $ 360,364 | $ 496 | $ 309,479 | $ 309,975 | 670,339 | |||||||||||||||||||||||
Conversion of 2015 Unit offering notes into shares of common stock (in shares) | 258,236 | |||||||||||||||||||||||||||||
Conversion of 2015 Unit offering notes into shares of common stock | $ 173 | 64,386 | 64,559 | |||||||||||||||||||||||||||
Stock option compensation expense | 1,831,313 | 1,831,313 | ||||||||||||||||||||||||||||
Warrants issued | $ 3,474,721 | $ 3,474,721 | $ 72,320 | $ 72,320 | ||||||||||||||||||||||||||
Investment into Clyra Medical Technologies | 750,000 | 750,000 | ||||||||||||||||||||||||||||
Net loss | (5,055,976) | (21,054) | (5,077,030) | |||||||||||||||||||||||||||
Foreign translation adjustment | (40,567) | (40,567) | ||||||||||||||||||||||||||||
Balance (in shares) at Dec. 31, 2015 | 85,648,015 | |||||||||||||||||||||||||||||
Balance at Dec. 31, 2015 | $ 57,236 | 84,410,821 | (84,075,695) | (40,567) | 789,573 | $ 1,141,368 | ||||||||||||||||||||||||
Issuance of stock in exchange for Clyra shares (in shares) | 2,818,271 | 2,818,271 | ||||||||||||||||||||||||||||
Issuance of stock in exchange for Clyra shares | $ 1,892 | 862,117 | $ 864,009 | |||||||||||||||||||||||||||
Issuance of common stock to vendors and interest to note holders (in shares) | 2,342,264 | |||||||||||||||||||||||||||||
Issuance of common stock to vendors and interest to note holders | $ 1,599 | $ 991,479 | $ 993,078 | 993,078 | ||||||||||||||||||||||||||
Conversion of 2015 Unit offering notes into shares of common stock (in shares) | 2,167,420 | |||||||||||||||||||||||||||||
Conversion of 2015 Unit offering notes into shares of common stock | $ 1,452 | 587,919 | 589,371 | |||||||||||||||||||||||||||
Stock option compensation expense | 751,113 | 751,113 | ||||||||||||||||||||||||||||
Warrants issued | $ 3,006,325 | $ 3,006,325 | ||||||||||||||||||||||||||||
Net loss | (7,839,731) | (234,604) | (8,074,335) | |||||||||||||||||||||||||||
Foreign translation adjustment | (41,127) | (41,127) | ||||||||||||||||||||||||||||
Balance (in shares) at Dec. 31, 2016 | 92,975,970 | |||||||||||||||||||||||||||||
Balance at Dec. 31, 2016 | $ 62,179 | $ 90,609,774 | $ (91,915,426) | $ (81,694) | $ 554,969 | $ (770,198) |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) | 12 Months Ended | |
Dec. 31, 2016 | Dec. 31, 2015 | |
Cash flows from operating activities | ||
Net loss | $ (8,074,335) | $ (5,077,030) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Stock option compensation expense | 751,113 | 1,831,313 |
Common stock issued for interest and in lieu of salary to officers and fees for services from consultants and officers and board of directors | 993,078 | 670,339 |
Interest expense related to amortization of the discount on convertible notes payable and line of credit and deferred financing costs | 2,610,764 | 808,572 |
Change in fair value of derivative warrant liability | 171,800 | |
Amortization and depreciation expense | 15,887 | 10,920 |
Changes in assets and liabilities: | ||
Accounts receivable | (26,563) | (35,814) |
Inventories | 2,989 | (11,921) |
Accounts payable and accrued expenses | (124,880) | (110,554) |
Accrued officer bonus | 80,000 | |
Deposits | (135,000) | 35,000 |
Prepaid expenses and other assets | 14,235 | (4,167) |
Net cash used in operating activities | (3,720,912) | (1,883,342) |
Cash flows from investing activities | ||
Equipment purchases | (61,931) | |
Net cash used in investing activities | (61,931) | |
Cash flows from financing activities | ||
Proceeds from convertible notes payable | 2,307,000 | 2,804,713 |
Proceeds from the sale of stock in majority-owned subsidiary | 750,000 | |
Proceeds from notes payable | 500,000 | |
Proceeds from line of credit | 300,000 | |
Proceeds from warrant exercise | 864,009 | |
Payment of financing costs | (22,150) | |
Net cash provided by financing activities | 3,971,009 | 3,532,563 |
Net effect of foreign currency translation | (41,127) | (40,567) |
Net change in cash | 147,039 | 1,608,654 |
Cash at beginning of year | 1,763,114 | 154,460 |
Cash at end of period | 1,910,153 | 1,763,114 |
Supplemental disclosures of cash flow information | ||
Interest | 9,855 | |
Income taxes | 7,681 | 4,000 |
Conversion of Convertible Notes Payable into Common Stock [Member] | ||
Non-cash investing and financing activities | ||
Conversion of debt | 589,371 | 276,576 |
Conversion of Lines of Credit into Convertible Notes Payable [Member] | ||
Non-cash investing and financing activities | ||
Conversion of debt | 250,000 | |
Warrants Issued in Conjunction with Convertible Notes and Letter of Credit [Member] | ||
Non-cash investing and financing activities | ||
Fair value of warrants issued | 3,006,325 | 3,474,721 |
Warrants Issued for Financing Fees [Member] | ||
Non-cash investing and financing activities | ||
Fair value of warrants issued | $ 72,320 |
Note 1 - Business and Organizat
Note 1 - Business and Organization | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | Note 1. Outlook The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of our business. For the year ended December 31, 2016, $8,074,335, December 31, 2016, $861,929, $2,016,682, $5,860,668, an accumulated deficit of $91,915,426, We have been, and anticipate that we will continue to be, limited in terms of our capital resources. Our total cash and cash equivalents were $1,910,153 December 31, 2016. December 31, 2016, $3,971,009 $281,106 December 31, 2016. 2017. Organization We were initially organized under the laws of the State of Florida in 1989, 1991 six 2006, 2009, 2013, 2014, 2016, 2016. 2012 9). Business Overview We feature three |
Note 2 - Summary of Significant
Note 2 - Summary of Significant Accounting Policies | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Significant Accounting Policies [Text Block] | Note 2. In the opinion of management, the accompanying balance sheets and related statements of operations, cash flows, and stockholders’ deficit include all adjustments, consisting only of normal recurring items, necessary for their fair presentation in conformity with accounting principles generally accepted in the United States of America. Principles of Consolidation The consolidated financial statements include the accounts of the Company and its majority owned subsidiaries. All intercompany accounts and transactions have been eliminated. Foreign Currency The Company has designated the functional currency of Biolargo Water, Inc., our Canadian subsidiary, to be the Canadian dollar. Therefore, transaction gains and losses resulting from differences in exchange rates are recorded in accumulated other comprehensive income. Cash and Cash Equivalents We consider all highly liquid investments with original maturities of three one December 31, 2016, $250,000 Accounts Receivable Trade accounts receivable are recorded net of allowances for doubtful accounts. Estimates for allowances for doubtful accounts are determined based on payment history and individual customer circumstances. The allowance for doubtful accounts was $3,818 December 31, 2015 $0 December 31, 2016. Inventory Inventories are stated at the lower of cost or net realizable value using the average cost method. Inventories consisted of: DECEMBER 31, 2015 DECEMBER 31, 2016 Raw material $ 12,162 $ 14,555 Finished goods 25,273 19,891 Total $ 37,435 $ 34,446 Other Assets Other Assets consists of payments made to purchase patents related to our efforts in commercializing the Isan system and a security deposit of $27,467 For each of the years ended December 31, 2015 2016 $ 10 Long-lived and definite lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may December 31, 2015 2016, Earnings (Loss) Per Share We report basic and diluted earnings (loss) per share (“EPS”) for common and common share equivalents. Basic EPS is computed by dividing reported earnings by the weighted average shares outstanding. Diluted EPS is computed by adding to the weighted average shares the dilutive effect if stock options and warrants were exercised into common stock. For the years ended December 31, 2015 2016, Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the period reported. Actual results could differ from those estimates. Estimates are used when accounting for stock-based transactions, debt transactions, derivative liabilities, allowance for bad debt, asset depreciation and amortization, and payroll taxes, among others. The methods, estimates and judgments we use in applying these most critical accounting policies have a significant impact on the results of our financial statements. Share-based Payments For stock and stock options issued to consultants and other non-employees for services, the Company measures and records an expense as of the earlier of the date at which either: a commitment for performance by the non-employee has been reached or the non-employee’s performance is complete. The equity instruments are measured at the current fair value, and for stock options, the instruments are measured at fair value using the Black Scholes options model. For equity instruments issued and outstanding where performance is not complete, but the instrument has been recorded, those instruments are measured again at their then current fair market values at each of the reporting dates (they are “marked-to market”) until the performance and the contract are complete. Non-Cash Transactions We have established a policy relative to the methodology to determine the value assigned to each intangible we acquire, and/or services or products received for non-cash consideration of our common stock. The value is based on the market price of our common stock issued as consideration, at the date of the agreement of each transaction or when the service is rendered or product is received. Revenue Recognition Revenues are recognized as risk and title to products transfers to the customer (which generally occurs at the time shipment is made), the sales price is fixed or determinable, and collectability is reasonably assured. Although we don’t have a history of returns, we guarantee satisfaction of many of our products and would accept returns if requested by our customer. We also may one Income Taxes The asset and liability approach is used to recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of asset and liabilities. Deferred tax assets and liabilities are determined based on the differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect on deferred tax asset and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. We account for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by generally accepted accounting principles (“GAAP”). Under GAAP, the tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of the position are recognized. Fair Value of Financial Instruments Management believes the carrying amounts of the Company's financial instruments as of December 31, 2015 2016 respective fair values because of the short-term nature of these instruments. Such instruments consist of cash, accounts receivable, prepaid assets, accounts payable, lines of credit, and other assets and liabilities. Government Grants We have been awarded grants from the Canadian National Research Institute – Industrial Research Assistance Program (NRC-IRAP) and the National Science and Engineering Research Council of Canada (NSERC). The government grants received are considered other income and are included in our consolidated statements of operations. We received our first 2015 30 $1,100,000. third six eighteen The grants provide for (i) recurring monthly amounts and (ii) reimbursement of costs for research talent for which we invoice to request payment and (iii) ancillary cost reimbursement for research talent travel related costs. All awarded grants have specific requirements on how the money is spent, typically to employ researchers. None of the funds may Recent Accounting Pronouncements In February 2016, 2016 02, "Leases (Topic 842)," December 15, 2018, In March 2016, 2016 09, Compensation—Stock Compensation (Topic 718): 2016 09 December 15, 2016, In April 2016, 2016 10, 606): 1. Identifying Performance Obligations: a. When identifying performance obligations, whether it is necessary to assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract. b. Determining whether promised goods and services are separately identifiable (that is, distinct within the context of the contract) c. Determining whether shipping and handling activities are a promised service in a contract or are activities to fulfill an entity’s other promises in the contract. 2. Licensing: a. Determining whether the nature of an entity’s promise in granting a license is to provide a right to access the entity’s intellectual property, which is satisfied over time and for which revenue is recognized over time, or to provide a right to use the entity’s intellectual property, which is satisfied at a point in time and for which revenue is recognized at a point in time. b. The scope and applicability of the guidance about when to recognize revenue for sales-based or usage-based royalties promised in exchange for a license of intellectual property c. Distinguishing contractual provisions that require an entity to transfer additional licenses (that is, rights to use or access intellectual property) to a customer from contractual provisions that define the 2 The amendments in this Update affect the guidance in Accounting Standards Update 2014 09, Revenue from Contracts with Customers (Topic 606), December 15, 2017. In April 2015, 2015 03, 835 30)”. |
Note 3 - Deposits
Note 3 - Deposits | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Deposit Liabilities Disclosures [Text Block] | Note 3. Licensing Revenue In 2012, 50/50 In February 2014, $100,000 August 12, 2014, 10 $100,000 10% 40% July 1, 2016, $50,000 July 1 December 31, 2016, 2, We are obligated to share any revenues under the agreement on an equal basis with Peter Holdings Pty. Ltd. On July 1, 2016, $100,000 2014 $45,000 Investor Deposit On December 18, 2015, $35,000 2015 4). December 31, 2015, 2016. |
Note 4 - Debt Obligations
Note 4 - Debt Obligations | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | Note 4. The following table summarizes our debt obligations outstanding as of the dates indicated: DECEMBER 31, 2015 DECEMBER 31, 2016 Convertible notes, mature June 1, 2018 $ 3,245,972 $ 4,800,097 Convertible notes, mature September 17, 2019 — 283,571 Convertible notes, mature July 8, 2017 — 280,000 Convertible notes, mature December 30, 2017 — 280,000 Convertible notes, mature December 31, 2019 — 167,000 Line of credit, matures December 1, 2017 — 50,000 Total $ 3,245,972 $ 5,860,668 The Unit Offerings of a convertible promissory note and a Series A stock purchase warrant are accounted for under the fair value and relative fair value method. The warrant is first If the warrant is determined to not have derivative features, it is recorded into equity at its fair value using the Black Scholes option model, however, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the convertible note. The convertible note is recorded at its fair value, limited to a relative fair value based upon the percentage of its fair value to the total fair value including the fair value of the warrant. Further, the convertible promissory note is examined for any intrinsic beneficial conversion feature (“BCF”) of which the convertible price of the note is less than the closing stock price on date of issuance. If the relative fair value method is used to value the convertible promissory note and there is an intrinsic BCF, a further analysis is undertaken of the BCF using an effective conversion price which assumes the conversion price is the relative fair value divided by the number of shares the convertible debt is converted into by its terms. The adjusted BCF value is accounted for as equity. The warrant and BCF fair values are also recorded as a discount to the convertible promissory notes. As present, these equity features of the convertible promissory notes have recorded a discount to the convertible notes that is substantially equal to the proceeds received. For the years ended December 31, 2015 2016 $994,671 $3,129,104 Convertible Notes, mature June 1, 2018 2015 On January 15, 2015, (“2015 September 16, 2016. five June 1, 2018. $3,000,000 Interest due will be paid quarterly in arrears in cash or shares of common stock; all interest due thus far has been paid in shares of common stock. If paid by the issuance of common stock, interest is paid at a conversion price equal to the average closing price of the Company’s common stock over the 20 may may ten three Each investor, for no additional consideration, received a Series A stock purchase warrant. (See Note 6). one June 1, 2020. may 30 ten two In total, we issued five Pricing Supplement Conversion Price Warrant Exercise Price Aggregate Investments No. 1 $ 0.25 $ 0.40 $ 460,000 No. 2 $ 0.25 $ 0.40 1,100,000 No. 3 $ 0.35 $ 0.45 1,546,713 No. 4 $ 0.35 $ 0.45 550,000 No. 5 $ 0.55 $ 0.70 1,155,000 $ 4,811,713 The closing stock price on December 30, 2016 $0.83 During the year ended December 31, 2016, $2,140,000 June 1, 2018, 12% $985,000 $0.35, $1,155,000 $0.55. 6.) During the year ended December 31, 2015, $2,671,713 June 1, 2018, 12% $1,535,000 $0.25, $1,136,713 $0.35. 6.) During the year ended December 31, 2016, $589,371 2015 2,167,420 5, December 31, 2016, $4,140,213 December/January Notes In January 2015, $133,000 one 12% $0.30 January 2018. 6). The funds received as part of our December/January Notes totaled $333,000. December 31, 2015, $383,913, 2015 $0.25 June 1, 2018. 1,909,301 $0.40 6). Summer 2014 Offering Conversions During 2015, 2014 2015 2015 530,000 2014 $212,000 $212,000 June 1, 2018. $50,000 On November 19, 2013, $50,000 24%. May 15, 2016. In September 2015, $58,530, 2015 June 1, 2018, $0.25 234,120 $0.40 One-Year Convertible Notes, mature July 8, 2017 December 30, 2017 On December 30, 2016, $250,000 $0.57 December 30, 2017 two $280,000. 3% 400,000 $0.75 five 1 January 24, 2017. may Thus, the warrants are presented as a derivative liability on our balance sheet. The fair value of these warrants was $331,760 $280,000 On July 8, 2016, we received $250,000 $0.45 July 8, 2017 two $280,000. 3% stock purchase warrants to purchase an aggregate 400,000 exercisable at $0.65 five may 2015 $160,000 $120,000 December 31, 2016 $171,800 $331,800. Line of Credit, matures December 1, 2017 On June 6, 2016, $300,000 18% may nine December 1, 2017. Each investor, for no additional consideration, received a warrant to purchase our common stock. (See Note 6). one On September 17, 2016, $250,000 2015 December 31, 2016, $50,000 Convertible Notes, mature September 17, 2019 On September 17, 2016, December 1, 2017, $250,000 $33,571 $283,571 2015 $0.55 September 17, 2019, June 1, 2018. 515,583 $0.70 6). Convertible Notes, mature December 31, 2019 2016 On December 27, 2016, 2016 $600,000 $0.57 December 31, 2019, 12% 20 may When paid in shares, the number of shares to be issued shall be calculated by dividing the principal amount invested by the $0.57 may ten three $0.57 one $0.70 December 31, 2021. The Company may 30 10 two 1 January 24, 2017. January 13, 2017 10). $167,000 three 292,983 6.) All of these offerings and sales were made in reliance on the exemption from registration contained in Section 4(2) |
Note 5 - Stockholders' Equity
Note 5 - Stockholders' Equity | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Compensation and Employee Benefit Plans [Text Block] | Note 5. Preferred Stock Our certificate of incorporation authorizes our Board of Directors to issue preferred stock, from time to time, on such terms and conditions as they shall determine. As of December 31, 2015 December 31, 2016 no Common Stock During the year ended December 31, 2016, 2,342,264 $993,078, . During the year ended December 31, 2015 2016, 258,236 2,167,420 $64,559 $589,371, During the year ended December 31, 2016, 2,818,271 $864,009 There were no shares issued for the exercise of warrants during 2015. During the year ended December 31, 2015, 1,370,480 $670,339, . Our total capitalization as of December 31, 2016 Description Shares Outstanding Common Stock: 92,975,970 Outstanding Options: 30,065,352 Outstanding Warrants: 20,035,114 Subtotal: 143,076,436 Shares issuable upon conversion of Convertible Promissory Notes: 15,063,278 Total* 158,139,714 The total shares issued in the above table of 158,139,714 Share-Based Compensation During the year ended December 31, 2015 2016, $1,831,313 $751,113, 2007 2007 2007 On August 7, 2007, April 29, 2011, 2007 (“2007 may may may 10 On June 20, 2016, 40,000 2007 $0.45 $18,000 On March 21, 2016, five 307,777 March 2011. March 21, 2021. $119,971 On September 30, 2015, February 1, 2008 September 30, 2015 September 30, 2016 February 1, 2015. 300,000 120,000 September 30, 2015, 15,000 December 31, 2015 2016, $94,050 $76,950 February 10, 2017, 300,000 $0.69 February 10, 2017. February 10, 2027, 125,000 February 10, 2017, 25,000 March 1, 2017, On June 24, 2015, five 1,772,581 August 4, 2010. $0.30 August 4, 2020. $620,403 On June 24, 2015, 40,000 2007 $0.38 $15,200 On June 24, 2015, five 200,000 February 2010. $0.575 February 5, 2020. $68,000 On April 20, 2015, 700,000 two ten $0.40 $0.34 $238,000 December 31, 2015 2016, $ 79,280 August 2016 262,500 Activity for our stock options under the 2007 December 31, 2015 2016 Weighted Average Options Shares Exercise Price per Outstanding Available Price per share share Balance, December 31, 2014 8,601,086 3,398,914 $0.23 - 1.89 $ 0.44 Granted 1,040,000 (1,040,000 ) 0.30 - 0.58 0.35 Plan classification 600,000 (600,000 ) 0.30 - 0.60 0.33 Balance, December 31, 2015 10,241,086 1,758,914 $0.22 - 1.89 $ 0.44 Granted 40,000 (40,000 ) 0.45 0.45 Exercised (102,000 ) — 0.35 0.35 Cancelled (262,500 ) 262,500 0.40 0.40 Balance, December 31, 2016 9,916,586 1,981,414 $0.22 - 1.89 $ 0.46 The following table summarizes the stock options issued under the 2007 December 31, 2016. Weighted Currently Exercisable Average Weighted Options Remaining Average Number Weighted Outstanding Contractual Exercise Of Shares Average at December 31, 2016 Exercise Price Life Price December 31, 2016 Exercise Price 525,000 $0.40 - 1.89 1 $ 1.06 525,000 $ 1.06 892,135 0.28 - 0.99 2 0.51 892,135 0.51 1,020,000 0.25 - 0.70 3 0.55 1,020,000 0.55 3,650,528 0.22 - 0.57 4 0.37 3,650,528 0.37 1,656,262 0.34 - 0.40 5 0.36 1,656,262 0.36 715,161 0.28 - 0.40 6 0.36 715,161 0.36 640,000 0.30 - 0.65 7 0.48 640,000 0.48 477,500 0.38 - 0.40 8 0.42 477,500 0.42 340,000 0.45 - 0.57 9 0.56 340,000 0.56 9,916,586 $0.22 - 1.89 5 $ 0.46 9,916,586 $ 0.46 Options issued Outside of the 2007 During the year ended December 31, 2016, 1,009,718 $0.33 $0.83 $316,007 $357,312 During the year ended December 31, 2015, 2,075,934 $0.33 $0.65 $942,509 $887,864 The grant-date fair value of the previously issued options that vested during the year ended December 31, 2015 2016 $74,145 $99,600, Activity of our stock options issued outside of the 2007 December 31, 2015 2016 Weighted Average Options Exercise Price per Outstanding Price per share share Balance, December 31, 2014 17,965,291 $0.18 - 1.00 $ 0.40 Granted 2,075,931 0.25 - 0.65 0.40 Expired (46,250 ) 0.30 0.30 Plan classification (600,000 ) 0.30 - 0.63 0.33 Balance, December 31, 2015 19,394,975 $0.18 - 1.00 $ 0.40 Granted 1,009,718 0.33 - 0.83 0.48 Exercised (255,927 ) 0.25 0.35 Balance, December 31, 2016 20,148,766 $0.18 - 1.00 $ 0.43 The following table summarizes the stock options issued outside of the 2007 December 31, 2016. Weighted Currently Exercisable Average Weighted Number of Options Remaining Average Shares at Weighted Outstanding at Contractual Exercise December 31, Average December 31, 2016 Exercise Price Life Price 2016 Exercise Price 7,733,259 $0.18 .25 $ 0.18 7,733,259 $ 0.18 2,400,000 0.99 .25 0.99 2,400,000 0.99 691,975 0.55 2 0.55 691,975 0.55 800,000 1.00 5 1.00 800,000 1.00 168,750 0.40 6 0.40 168,750 0.40 1,497,986 0.30 6 0.30 1,497,986 0.30 3,122,093 0.25 - 0.65 7 0.32 3,122,093 0.32 2,120,947 0.33 - 0.47 8 0.37 2,120,947 0.37 1,388,166 0.33 - 0.65 9 0.47 1,238,116 0.47 225,641 0.60 - 0.83 10 0.76 225,641 0.76 20,148,766 $0.18 - 1.00 4 $ 0.40 19,998,766 $ 0.40 We recognize compensation expense for stock option awards on a straight-line basis for employees over the applicable service period of the award, which is the vesting period. Share-based compensation expense is based on the grant date fair value estimated using the Black-Scholes Option Pricing Model. The following methodology and assumptions were used to calculate share based compensation for the year ended December 31: 2015 2016 Non Plan 2007 Plan Non Plan 2007 Plan Risk free interest rate 1.83 - 2.33% 1.60 - 2.38% 1.91 - 2.49% 1.36 - 2.14% Expected volatility 794 - 821% 322 - 807% 623 - 738% 315 - 794% Expected dividend yield - - - - Forfeiture rate - - - - Life in years 7 3 - 7 7 5 Expected price volatility is the measure by which our stock price is expected to fluctuate during the expected term of an option. Expected volatility is derived from the historical daily change in the market price of our common stock, as we believe that historical volatility is the best indicator of future volatility. The risk-free interest rate used in the Black-Scholes calculation is based on the prevailing U.S Treasury yield as determined by the U.S. Federal Reserve. We have never paid any cash dividends on our common stock and do not anticipate paying cash dividends on our common stock in the foreseeable future. Historically, we have not had significant forfeitures of unvested stock options granted to employees and Directors. A significant number of our stock option grants are fully vested at issuance or have short vesting provisions. Therefore, we have estimated the forfeiture rate of our outstanding stock options as zero. |
Note 6 - Warrants
Note 6 - Warrants | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Warrants [Text Block] | Note 6. Series A Warrants Pursuant to the terms of our 2015 December 31, 2016, 5,429,872 2,814,286 $0.45 2,615,586 $0.70 2015 4), 2015 4,059,744 June 1, 2020 854,545 July 31, 2021. $2,115,874recorded Pursuant to the terms of our 2015 December 31, 2015, 9,597,123 6,320,800 $0.40 3,276,323 $0.45 June 1, 2020. $3,319,906 Warrants Issued Concurrently with Line of Credit During the year ended December 31, 2016 300,000 $0.35 June 2021. $237,405 Pursuant to the terms of our line of credit, five 2015 $283,571 4 5). 515,583 $0.70 June 1, 2018. $283,571 Warrants Issued Concurrently with One Year Convertible Note s On July 8, 2016 400,000 $0.65 July 8, 2021. $160,000 one may 2015 On December 30, 2016 400,000 $0.75 December 30, 2021. $280,000 one may 2015 Warrants Issued Concurrently with Winter 2016 On December 28, 2016 292,983 2016 4). $0.70 December 31, 2021. $167,000 Warrants Issued Concurrently with December/January Notes During the year ended December 31, 2015, 266,000 5). $0.30 January 2020. $133,000 We have certain warrants outstanding to purchase our common stock, at various prices, as described in the following table: Number of Shares Price Range Outstanding as of December 31, 2014 8,838,122 $0.125 - 1.00 Issued 12,693,395 0.30 - 0.45 Exercised — 0.30 - 0.50 Expired (7,752,079 ) 0.25 - 0.75 Outstanding as of December 31, 2015 13,779,438 $0.125 - 1.00 Prior year extensions 4,634,637 0.30 Issued 6,822,855 0.35 - 0.75 Exercised (2,818,271 ) 0.25 - 0.40 Expired (2,383,545 ) 0.55 - 0.75 Outstanding as of December 31, 2016 20,035,114 $0.125 - 1.00 To determine interest expense related to our outstanding warrants issued in conjunction with debt offerings, the fair value of each award grant is estimated on the date of grant using the Black-Scholes option-pricing model and the relative fair values are amortized over the life of the warrant. The determination of expense of warrants issued for services or settlement also uses the option-pricing model. The principal assumptions we used in applying this model were as follows: 2015 2016 Risk free interest rate .97 - 1.60% .95 - 1.96% Expected volatility 255 - 332% 301 - 315% Expected dividend yield - - Forfeiture rate - - Expected life in years 3 - 5 3 - 5 The risk-free interest rate is based on U.S Treasury yields in effect at the time of grant. Expected volatilities are based on historical volatility of our common stock. The expected life in years is based on the contract term of the warrant. |
Note 7 - Accounts Payable and A
Note 7 - Accounts Payable and Accrued Expenses | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | Note 7. Accounts payable and accrued expenses included the following: December 31, December 31, 2015 2016 Accounts payable $ 174,539 $ 22,231 Payroll tax liability 137,500 137,500 Officer bonus — 80,000 Accrued interest 12,944 40,372 Total Accounts Payable and Accrued Expenses $ 324,983 $ 280,103 The payroll tax liability is our estimate of payroll taxes due on the past services of independent contractors. We are currently attempting to reduce the liability to approximately $5,000 On September 27, 2016, $ 60,000 December 31, 2016, $80,000 January 2017, $ 40,000 Issuance of Common Stock in exchange for payment of payables Payment of Officer Salaries During 2015 738,837 $0.35 $0.36 $309,975 2016 Payment of Consultant Fees and Accrued Interest During 2016, 2,342,264 $0.25 $0.83 $993,078 During 2015 631,643 $0.35 $0.36 $360,364 All of these offerings and sales were made in reliance on the exemption from registration contained in Section 4(2) |
Note 8 - Provision for Income T
Note 8 - Provision for Income Taxes | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | Note 8. Given our historical losses from operations, income taxes have been limited to the minimum franchise tax assessed by the State of California. At December 31, 2016, $45 2002 2007, may 20 2021. 100% At December 31, 2016, 2012 2015 2007 |
Note 9 - Noncontrolling Interes
Note 9 - Noncontrolling Interest | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Noncontrolling Interest Disclosure [Text Block] | Note 9. Clyra In May 2012, December 17, 2012, 7,500 December 17, 2012, 1,500 three one third three On December 30, 2015, 9,830 $750,000. 4(2) 40% 54%, As set forth in Clyra’s Amended and Restated Articles of Incorporation, Preferred Shares accrue an annual dividend of 8% five 510(k) December 20, December 31, 2016 $60,000. Holders of Preferred Shares are entitled to preferential payments in the event of a liquidation, dissolution or winding up of the company, in an amount equal to any accrued and unpaid dividends. After such preference, any remaining assets are distributed pro-rata between holders of Clyra common stock and Preferred Shares as if the Preferred Shares had converted to Clyra common stock. Holders of Preferred Shares may one one In addition to the foregoing, Clyra entered into a consulting agreement with Beach House Consulting, LLC, through which Jack B. Strommen will be providing consulting services to the company. Mr. Strommen is the founder of Beach House Consulting, LLC. Mr. Strommen will be assisting the company in its sales and marketing activities once it has FDA Approval on a product, at which point the agreement provides that Mr. Strommen is to receive $23,438 four December 31, 2016, For the year ended December 31, 2015 2016, $115,859 $508,414. Biolargo Maritime Solutions The Company has an additional subsidiary, Biolargo Maritime Solutions, whereby if certain factors are met, a noncontrolling equity interest in this subsidiary has been pledged to its management. |
Note 10 - Subsequent Events
Note 10 - Subsequent Events | 12 Months Ended |
Dec. 31, 2016 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | Note 10. Management has evaluated subsequent events through the date of the filing of this Annual Report and management noted the following for disclosure. Unit Offering During the three March 31, 2017, $125,000 five 5). December 31, 2019, 12% $0.70. 219,298 7.) Conversion of Notes due July 8, 2017 On January 13, 2017, July 8, 2017, $280,000 4), 640,889 |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 12 Months Ended |
Dec. 31, 2016 | |
Accounting Policies [Abstract] | |
Consolidation, Policy [Policy Text Block] | Principles of Consolidation The consolidated financial statements include the accounts of the Company and its majority owned subsidiaries. All intercompany accounts and transactions have been eliminated. |
Foreign Currency Transactions and Translations Policy [Policy Text Block] | Foreign Currency The Company has designated the functional currency of Biolargo Water, Inc., our Canadian subsidiary, to be the Canadian dollar. Therefore, transaction gains and losses resulting from differences in exchange rates are recorded in accumulated other comprehensive income. |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash and Cash Equivalents We consider all highly liquid investments with original maturities of three one December 31, 2016, $250,000 |
Receivables, Policy [Policy Text Block] | Accounts Receivable Trade accounts receivable are recorded net of allowances for doubtful accounts. Estimates for allowances for doubtful accounts are determined based on payment history and individual customer circumstances. The allowance for doubtful accounts was $3,818 December 31, 2015 $0 December 31, 2016. |
Inventory, Policy [Policy Text Block] | Inventory Inventories are stated at the lower of cost or net realizable value using the average cost method. Inventories consisted of: DECEMBER 31, 2015 DECEMBER 31, 2016 Raw material $ 12,162 $ 14,555 Finished goods 25,273 19,891 Total $ 37,435 $ 34,446 |
Intangible Assets, Finite-Lived, Policy [Policy Text Block] | Other Assets Other Assets consists of payments made to purchase patents related to our efforts in commercializing the Isan system and a security deposit of $27,467 For each of the years ended December 31, 2015 2016 $ 10 Long-lived and definite lived intangible assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may December 31, 2015 2016, |
Earnings Per Share, Policy [Policy Text Block] | Earnings (Loss) Per Share We report basic and diluted earnings (loss) per share (“EPS”) for common and common share equivalents. Basic EPS is computed by dividing reported earnings by the weighted average shares outstanding. Diluted EPS is computed by adding to the weighted average shares the dilutive effect if stock options and warrants were exercised into common stock. For the years ended December 31, 2015 2016, |
Use of Estimates, Policy [Policy Text Block] | Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and revenues and expenses during the period reported. Actual results could differ from those estimates. Estimates are used when accounting for stock-based transactions, debt transactions, derivative liabilities, allowance for bad debt, asset depreciation and amortization, and payroll taxes, among others. The methods, estimates and judgments we use in applying these most critical accounting policies have a significant impact on the results of our financial statements. |
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] | Share-based Payments For stock and stock options issued to consultants and other non-employees for services, the Company measures and records an expense as of the earlier of the date at which either: a commitment for performance by the non-employee has been reached or the non-employee’s performance is complete. The equity instruments are measured at the current fair value, and for stock options, the instruments are measured at fair value using the Black Scholes options model. For equity instruments issued and outstanding where performance is not complete, but the instrument has been recorded, those instruments are measured again at their then current fair market values at each of the reporting dates (they are “marked-to market”) until the performance and the contract are complete. |
Non Cash Transactions [Policy Text Block] | Non-Cash Transactions We have established a policy relative to the methodology to determine the value assigned to each intangible we acquire, and/or services or products received for non-cash consideration of our common stock. The value is based on the market price of our common stock issued as consideration, at the date of the agreement of each transaction or when the service is rendered or product is received. |
Revenue Recognition, Policy [Policy Text Block] | Revenue Recognition Revenues are recognized as risk and title to products transfers to the customer (which generally occurs at the time shipment is made), the sales price is fixed or determinable, and collectability is reasonably assured. Although we don’t have a history of returns, we guarantee satisfaction of many of our products and would accept returns if requested by our customer. We also may one |
Income Tax, Policy [Policy Text Block] | Income Taxes The asset and liability approach is used to recognize deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of asset and liabilities. Deferred tax assets and liabilities are determined based on the differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The effect on deferred tax asset and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. We account for uncertainties in income tax law under a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns as prescribed by generally accepted accounting principles (“GAAP”). Under GAAP, the tax effects of a position are recognized only if it is “more-likely-than-not” to be sustained by the taxing authority as of the reporting date. If the tax position is not considered “more-likely-than-not” to be sustained, then no benefits of the position are recognized. |
Fair Value of Financial Instruments, Policy [Policy Text Block] | Fair Value of Financial Instruments Management believes the carrying amounts of the Company's financial instruments as of December 31, 2015 2016 respective fair values because of the short-term nature of these instruments. Such instruments consist of cash, accounts receivable, prepaid assets, accounts payable, lines of credit, and other assets and liabilities. |
Government Grants [Policy Text Block] | Government Grants We have been awarded grants from the Canadian National Research Institute – Industrial Research Assistance Program (NRC-IRAP) and the National Science and Engineering Research Council of Canada (NSERC). The government grants received are considered other income and are included in our consolidated statements of operations. We received our first 2015 30 $1,100,000. third six eighteen The grants provide for (i) recurring monthly amounts and (ii) reimbursement of costs for research talent for which we invoice to request payment and (iii) ancillary cost reimbursement for research talent travel related costs. All awarded grants have specific requirements on how the money is spent, typically to employ researchers. None of the funds may |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Pronouncements In February 2016, 2016 02, "Leases (Topic 842)," December 15, 2018, In March 2016, 2016 09, Compensation—Stock Compensation (Topic 718): 2016 09 December 15, 2016, In April 2016, 2016 10, 606): 1. Identifying Performance Obligations: a. When identifying performance obligations, whether it is necessary to assess whether promised goods or services are performance obligations if they are immaterial in the context of the contract. b. Determining whether promised goods and services are separately identifiable (that is, distinct within the context of the contract) c. Determining whether shipping and handling activities are a promised service in a contract or are activities to fulfill an entity’s other promises in the contract. 2. Licensing: a. Determining whether the nature of an entity’s promise in granting a license is to provide a right to access the entity’s intellectual property, which is satisfied over time and for which revenue is recognized over time, or to provide a right to use the entity’s intellectual property, which is satisfied at a point in time and for which revenue is recognized at a point in time. b. The scope and applicability of the guidance about when to recognize revenue for sales-based or usage-based royalties promised in exchange for a license of intellectual property c. Distinguishing contractual provisions that require an entity to transfer additional licenses (that is, rights to use or access intellectual property) to a customer from contractual provisions that define the 2 The amendments in this Update affect the guidance in Accounting Standards Update 2014 09, Revenue from Contracts with Customers (Topic 606), December 15, 2017. In April 2015, 2015 03, 835 30)”. |
Note 2 - Summary of Significa18
Note 2 - Summary of Significant Accounting Policies (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
Notes Tables | |
Schedule of Inventory, Current [Table Text Block] | DECEMBER 31, 2015 DECEMBER 31, 2016 Raw material $ 12,162 $ 14,555 Finished goods 25,273 19,891 Total $ 37,435 $ 34,446 |
Note 4 - Debt Obligations (Tabl
Note 4 - Debt Obligations (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
Notes Tables | |
Schedule of Debt [Table Text Block] | DECEMBER 31, 2015 DECEMBER 31, 2016 Convertible notes, mature June 1, 2018 $ 3,245,972 $ 4,800,097 Convertible notes, mature September 17, 2019 — 283,571 Convertible notes, mature July 8, 2017 — 280,000 Convertible notes, mature December 30, 2017 — 280,000 Convertible notes, mature December 31, 2019 — 167,000 Line of credit, matures December 1, 2017 — 50,000 Total $ 3,245,972 $ 5,860,668 |
Convertible Debt [Table Text Block] | Pricing Supplement Conversion Price Warrant Exercise Price Aggregate Investments No. 1 $ 0.25 $ 0.40 $ 460,000 No. 2 $ 0.25 $ 0.40 1,100,000 No. 3 $ 0.35 $ 0.45 1,546,713 No. 4 $ 0.35 $ 0.45 550,000 No. 5 $ 0.55 $ 0.70 1,155,000 $ 4,811,713 |
Note 5 - Stockholders' Equity (
Note 5 - Stockholders' Equity (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
Notes Tables | |
Schedule of Capitalization [Table Text Block] | Description Shares Outstanding Common Stock: 92,975,970 Outstanding Options: 30,065,352 Outstanding Warrants: 20,035,114 Subtotal: 143,076,436 Shares issuable upon conversion of Convertible Promissory Notes: 15,063,278 Total* 158,139,714 |
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] | Weighted Average Options Shares Exercise Price per Outstanding Available Price per share share Balance, December 31, 2014 8,601,086 3,398,914 $0.23 - 1.89 $ 0.44 Granted 1,040,000 (1,040,000 ) 0.30 - 0.58 0.35 Plan classification 600,000 (600,000 ) 0.30 - 0.60 0.33 Balance, December 31, 2015 10,241,086 1,758,914 $0.22 - 1.89 $ 0.44 Granted 40,000 (40,000 ) 0.45 0.45 Exercised (102,000 ) — 0.35 0.35 Cancelled (262,500 ) 262,500 0.40 0.40 Balance, December 31, 2016 9,916,586 1,981,414 $0.22 - 1.89 $ 0.46 |
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] | 2015 2016 Non Plan 2007 Plan Non Plan 2007 Plan Risk free interest rate 1.83 - 2.33% 1.60 - 2.38% 1.91 - 2.49% 1.36 - 2.14% Expected volatility 794 - 821% 322 - 807% 623 - 738% 315 - 794% Expected dividend yield - - - - Forfeiture rate - - - - Life in years 7 3 - 7 7 5 |
Outside of 2007 Plan [Member] | |
Notes Tables | |
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] | Weighted Average Options Exercise Price per Outstanding Price per share share Balance, December 31, 2014 17,965,291 $0.18 - 1.00 $ 0.40 Granted 2,075,931 0.25 - 0.65 0.40 Expired (46,250 ) 0.30 0.30 Plan classification (600,000 ) 0.30 - 0.63 0.33 Balance, December 31, 2015 19,394,975 $0.18 - 1.00 $ 0.40 Granted 1,009,718 0.33 - 0.83 0.48 Exercised (255,927 ) 0.25 0.35 Balance, December 31, 2016 20,148,766 $0.18 - 1.00 $ 0.43 |
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block] | Weighted Currently Exercisable Average Weighted Number of Options Remaining Average Shares at Weighted Outstanding at Contractual Exercise December 31, Average December 31, 2016 Exercise Price Life Price 2016 Exercise Price 7,733,259 $0.18 .25 $ 0.18 7,733,259 $ 0.18 2,400,000 0.99 .25 0.99 2,400,000 0.99 691,975 0.55 2 0.55 691,975 0.55 800,000 1.00 5 1.00 800,000 1.00 168,750 0.40 6 0.40 168,750 0.40 1,497,986 0.30 6 0.30 1,497,986 0.30 3,122,093 0.25 - 0.65 7 0.32 3,122,093 0.32 2,120,947 0.33 - 0.47 8 0.37 2,120,947 0.37 1,388,166 0.33 - 0.65 9 0.47 1,238,116 0.47 225,641 0.60 - 0.83 10 0.76 225,641 0.76 20,148,766 $0.18 - 1.00 4 $ 0.40 19,998,766 $ 0.40 |
The 2007 Equity Incentive Plan [Member] | |
Notes Tables | |
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block] | Weighted Currently Exercisable Average Weighted Options Remaining Average Number Weighted Outstanding Contractual Exercise Of Shares Average at December 31, 2016 Exercise Price Life Price December 31, 2016 Exercise Price 525,000 $0.40 - 1.89 1 $ 1.06 525,000 $ 1.06 892,135 0.28 - 0.99 2 0.51 892,135 0.51 1,020,000 0.25 - 0.70 3 0.55 1,020,000 0.55 3,650,528 0.22 - 0.57 4 0.37 3,650,528 0.37 1,656,262 0.34 - 0.40 5 0.36 1,656,262 0.36 715,161 0.28 - 0.40 6 0.36 715,161 0.36 640,000 0.30 - 0.65 7 0.48 640,000 0.48 477,500 0.38 - 0.40 8 0.42 477,500 0.42 340,000 0.45 - 0.57 9 0.56 340,000 0.56 9,916,586 $0.22 - 1.89 5 $ 0.46 9,916,586 $ 0.46 |
Note 6 - Warrants (Tables)
Note 6 - Warrants (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
Notes Tables | |
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] | Number of Shares Price Range Outstanding as of December 31, 2014 8,838,122 $0.125 - 1.00 Issued 12,693,395 0.30 - 0.45 Exercised — 0.30 - 0.50 Expired (7,752,079 ) 0.25 - 0.75 Outstanding as of December 31, 2015 13,779,438 $0.125 - 1.00 Prior year extensions 4,634,637 0.30 Issued 6,822,855 0.35 - 0.75 Exercised (2,818,271 ) 0.25 - 0.40 Expired (2,383,545 ) 0.55 - 0.75 Outstanding as of December 31, 2016 20,035,114 $0.125 - 1.00 |
Schedule Of Assumptions Used To Determine Fair Value Of Warrants [Table Text Block] | 2015 2016 Risk free interest rate .97 - 1.60% .95 - 1.96% Expected volatility 255 - 332% 301 - 315% Expected dividend yield - - Forfeiture rate - - Expected life in years 3 - 5 3 - 5 |
Note 7 - Accounts Payable and22
Note 7 - Accounts Payable and Accrued Expenses (Tables) | 12 Months Ended |
Dec. 31, 2016 | |
Notes Tables | |
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] | December 31, December 31, 2015 2016 Accounts payable $ 174,539 $ 22,231 Payroll tax liability 137,500 137,500 Officer bonus — 80,000 Accrued interest 12,944 40,372 Total Accounts Payable and Accrued Expenses $ 324,983 $ 280,103 |
Note 1 - Business and Organiz23
Note 1 - Business and Organization (Details Textual) - USD ($) | 12 Months Ended | ||
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | $ (8,074,335) | $ (5,077,030) | |
Working Capital | 861,929 | ||
Assets, Current | 2,016,682 | 1,891,147 | |
Long-term Debt | 5,860,668 | 3,245,972 | |
Retained Earnings (Accumulated Deficit) | (91,915,426) | (84,075,695) | |
Cash and Cash Equivalents, at Carrying Value | 1,910,153 | 1,763,114 | $ 154,460 |
Net Cash Provided by (Used in) Financing Activities, Continuing Operations | 3,971,009 | $ 3,532,563 | |
Revenues | $ 281,106 |
Note 2 - Summary of Significa24
Note 2 - Summary of Significant Accounting Policies (Details Textual) | 12 Months Ended | |
Dec. 31, 2016USD ($) | Dec. 31, 2015USD ($) | |
Allowance for Doubtful Accounts Receivable, Current | $ 0 | $ 3,818 |
Amortization of Intangible Assets | $ 10,920 | $ 10,920 |
Canadian Government Grants [Member] | ||
Number of Grants Received | 30 | |
Grants Receivable | $ 1,100,000 | |
Canadian Government Grants [Member] | Minimum [Member] | ||
Grant Term | 180 days | |
Canadian Government Grants [Member] | Maximum [Member] | ||
Grant Term | 1 year 180 days | |
Other Assets [Member] | ||
Deposits Assets, Noncurrent | $ 27,467 |
Note 2 - Summary of Significa25
Note 2 - Summary of Significant Accounting Policies - Inventories (Details) - USD ($) | Dec. 31, 2016 | Dec. 31, 2015 |
Raw material | $ 14,555 | $ 12,162 |
Finished goods | 19,891 | 25,273 |
Total | $ 34,446 | $ 37,435 |
Note 3 - Deposits (Details Text
Note 3 - Deposits (Details Textual) - USD ($) | Jul. 01, 2016 | Aug. 12, 2014 | Dec. 31, 2016 | Dec. 31, 2012 | Dec. 31, 2015 | Dec. 18, 2015 |
Customer Deposits, Current | $ 135,000 | |||||
Peter Holdings Ltd [Member] | ||||||
Joint Venture Royalties Percentage | 50.00% | |||||
Peter Holdings Ltd [Member] | Licensing Agreements [Member] | Isan System License Agreement [Member] | Clarion Water [Member] | ||||||
Customer Deposits, Current | $ 100,000 | |||||
License Agreement Term | 10 years | |||||
Royalty As Percentage of Sales | 10.00% | |||||
Royalty as Percentage of Sublicensing Fees | 40.00% | |||||
Peter Holdings Ltd [Member] | Licensing Agreements [Member] | Isan System License Agreement [Member] | Clarion Water [Member] | Beginning July 1 2016 [Member] | ||||||
Quarterly Payments from Licensee | $ 45,000 | $ 50,000 | ||||
Potential Investor in 2015 Unit Offering [Member] | ||||||
Customer Deposits, Current | $ 35,000 |
Note 4 - Debt Obligations (Deta
Note 4 - Debt Obligations (Details Textual) | Dec. 30, 2016USD ($)$ / sharesshares | Dec. 27, 2016USD ($)$ / sharesshares | Sep. 17, 2016USD ($)$ / sharesshares | Jul. 08, 2016USD ($)$ / sharesshares | Jun. 06, 2016USD ($)shares | Jan. 15, 2015USD ($) | Nov. 19, 2013USD ($) | Jan. 31, 2015USD ($)$ / shares | Dec. 31, 2016USD ($)$ / sharesshares | Dec. 31, 2015USD ($)$ / sharesshares | Dec. 28, 2016$ / sharesshares | Sep. 30, 2015USD ($)$ / sharesshares |
Interest Expense, Debt | $ 3,129,104 | $ 994,671 | ||||||||||
Share Price | $ / shares | $ 0.83 | |||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 0.25 | |||||||||||
Proceeds from Long-term Lines of Credit | $ 50,000 | |||||||||||
Line of Credit Facility, Interest Rate at Period End | 24.00% | |||||||||||
Line of Credit Facility, Canceled | $ 58,530 | |||||||||||
Derivative Liability, Current | 663,560 | |||||||||||
Proceeds from Lines of Credit | $ 300,000 | 300,000 | ||||||||||
Line of Credit Facility, Interest Rate During Period | 18.00% | |||||||||||
Line of Credit, Current | $ 50,000 | |||||||||||
Conversion of Line of Credit to 2015 Unit Offering [Member] | ||||||||||||
Debt Conversion, Original Debt, Amount | $ 250,000 | |||||||||||
Debt Conversion, Original Debt, Accrued Interest Amount | $ 33,571 | |||||||||||
Line of Credit [Member] | ||||||||||||
Debt Instrument, Term | 270 days | |||||||||||
Summer 2014 Offering Conversions [Member] | ||||||||||||
Common Stock, Cancelled | shares | 530,000 | |||||||||||
Common Stock, Cancelled Value | $ 212,000 | |||||||||||
Winter 2016 Unit Offering [Member] | ||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | |||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 0.57 | |||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.70 | $ 0.70 | ||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 292,983 | 292,983 | ||||||||||
Units Issued During Period, Value, New Issues | $ 600,000 | |||||||||||
Number of Trading Days Prior to Interest Payment Due Date if Paid by Issuance of Common Stock | 20 days | |||||||||||
Debt Conversion before Maturity, Number of Trading Days Common Stock Closes at or above 3 Times the Unit Price | 10 days | |||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | shares | 1 | |||||||||||
Class of Warrant or Right, Exercise Period | 30 days | |||||||||||
Class of Warrant or Right, Exercise Period Condition, Number of Trading Days Common Stock Closes at or above 2 Times the Exercise Price | 10 days | |||||||||||
Proceeds from Issuance of Units | $ 167,000 | |||||||||||
December/January Notes [Member] | ||||||||||||
Proceeds from Convertible Debt | $ 133,000 | $ 333,000 | ||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | |||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 0.25 | |||||||||||
Debt Conversion, Original Debt, Amount | $ 383,913 | |||||||||||
One Year Convertible Notes [Member] | ||||||||||||
Proceeds from Convertible Debt | $ 250,000 | $ 250,000 | ||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 3.00% | 3.00% | ||||||||||
Debt Instrument, Face Amount | $ 280,000 | $ 280,000 | ||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 0.57 | $ 0.45 | ||||||||||
Debt Instrument, Unamortized Discount | $ 280,000 | |||||||||||
Convertible Notes Maturing on September 17, 2019 [Member] | ||||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 0.55 | |||||||||||
Long-term Debt, Gross | $ 283,571 | |||||||||||
Series A Warrant [Member] | ||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 5,429,872 | 9,597,123 | ||||||||||
Warrant Issued in Exchange of December/January Notes [Member] | ||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.30 | $ 0.40 | ||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 1,909,301 | |||||||||||
Series A Warrant Issued for Exchanged Equity [Member] | ||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.40 | |||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 234,120 | |||||||||||
Warrants Issued Concurrently With One Year Convertible Note [Member] | ||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.75 | $ 0.65 | ||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 400,000 | 400,000 | ||||||||||
Class of Warrant or Right, Expiration Term | 5 years | 5 years | ||||||||||
Derivative Liability, Current | $ 331,760 | $ 160,000 | $ 331,800 | |||||||||
Debt Instrument, Unamortized Discount | $ 120,000 | |||||||||||
Increase (Decrease) in Derivative Liabilities | $ 171,800 | |||||||||||
Warrants Issued Concurrently with Line of Credit [Member] | ||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.35 | |||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 300,000 | |||||||||||
Debt Instrument, Unamortized Discount | $ 237,405 | |||||||||||
Class of Warrant or Right, Number of Warrants Per Each Dollar Invested | shares | 1 | |||||||||||
Warrant Issued in Exchange of Cancelled Line of Credit [Member] | ||||||||||||
Debt Conversion, Original Debt, Amount | $ 283,571 | |||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.70 | $ 0.70 | ||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | shares | 515,583 | 515,583 | ||||||||||
The 2015 Unit Offering [Member] | ||||||||||||
Minimum Proceeds Required For Stock Registration | $ 3,000,000 | |||||||||||
Proceeds from Convertible Debt | $ 2,140,000 | $ 2,671,713 | ||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | 12.00% | ||||||||||
Debt Conversion, Original Debt, Amount | $ 589,371 | |||||||||||
Debt Conversion, Converted Instrument, Shares Issued | shares | 2,167,420 | |||||||||||
Convertible Notes Payable | $ 4,140,213 | |||||||||||
The 2015 Unit Offering [Member] | Debt Instrument, Convertible, Unit Price 1 [Member] | ||||||||||||
Debt Instrument, Face Amount | $ 985,000 | $ 1,535,000 | ||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 0.35 | $ 0.25 | ||||||||||
The 2015 Unit Offering [Member] | Debt Instrument, Convertible, Unit Price 2 [Member] | ||||||||||||
Debt Instrument, Face Amount | $ 1,155,000 | |||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 0.55 | |||||||||||
The 2015 Unit Offering [Member] | Debt Instrument, Convertible, Units Price 2 [Member] | ||||||||||||
Debt Instrument, Face Amount | $ 1,136,713 | |||||||||||
Debt Instrument, Convertible, Conversion Price | $ / shares | $ 0.35 | |||||||||||
The 2015 Unit Offering [Member] | New Convertible Promissory Note in Exchange of Cancelled Common Stock [Member] | ||||||||||||
Debt Instrument, Face Amount | $ 212,000 | |||||||||||
The 2015 Unit Offering [Member] | Series A Warrant [Member] | ||||||||||||
Class of Warrant or Right, Call Provision, Stock Price Threshold, Consecutive Business Days | 10 days | |||||||||||
Warrant, Convertible Conversion Ratio | 2 |
Note 4 - Debt Obligations - Sch
Note 4 - Debt Obligations - Schedule of Debt (Details) - USD ($) | Dec. 31, 2016 | Dec. 31, 2015 |
Convertible notes | $ 5,250,668 | $ 3,245,972 |
Convertible notes | 560,000 | |
Line of Credit, Current | 50,000 | |
Long-term Debt | 5,860,668 | 3,245,972 |
Convertible Notes Maturing on June 1, 2018 [Member] | ||
Convertible notes | 4,800,097 | 3,245,972 |
Convertible Notes Maturing on September 17, 2019 [Member] | ||
Convertible notes | 283,571 | |
Convertible Notes Maturing on July 8, 2017 [Member] | ||
Convertible notes | 280,000 | |
Convertible Notes Maturing on December 30, 2017 [Member] | ||
Convertible notes | 280,000 | |
Convertible Notes Maturing on December 31, 2019 [Member] | ||
Convertible notes | $ 167,000 |
Note 4 - Debt Obligations - Pri
Note 4 - Debt Obligations - Pricing Supplements (Details) - USD ($) | Dec. 31, 2016 | Dec. 31, 2015 | Sep. 30, 2015 |
Conversion Price (in dollars per share) | $ 0.25 | ||
Aggregate Investments | $ 5,250,668 | $ 3,245,972 | |
The 2015 Unit Offering [Member] | |||
Aggregate Investments | $ 4,811,713 | ||
Pricing Supplement No.1 [Member] | The 2015 Unit Offering [Member] | |||
Conversion Price (in dollars per share) | $ 0.25 | ||
Warrant Exercise Price (in dollars per share) | $ 0.40 | ||
Aggregate Investments | $ 460,000 | ||
Pricing Supplement No.2 [Member] | The 2015 Unit Offering [Member] | |||
Conversion Price (in dollars per share) | $ 0.25 | ||
Warrant Exercise Price (in dollars per share) | $ 0.40 | ||
Aggregate Investments | $ 1,100,000 | ||
Pricing Supplement No.3 [Member] | The 2015 Unit Offering [Member] | |||
Conversion Price (in dollars per share) | $ 0.35 | ||
Warrant Exercise Price (in dollars per share) | $ 0.45 | ||
Aggregate Investments | $ 1,546,713 | ||
Pricing Supplement No.4 [Member] | The 2015 Unit Offering [Member] | |||
Conversion Price (in dollars per share) | $ 0.35 | ||
Warrant Exercise Price (in dollars per share) | $ 0.45 | ||
Aggregate Investments | $ 550,000 | ||
Pricing Supplement No.5 [Member] | The 2015 Unit Offering [Member] | |||
Conversion Price (in dollars per share) | $ 0.55 | ||
Warrant Exercise Price (in dollars per share) | $ 0.70 | ||
Aggregate Investments | $ 1,155,000 |
Note 5 - Stockholders' Equity30
Note 5 - Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, Rate in Thousands | Feb. 10, 2017 | Aug. 31, 2016 | Jun. 20, 2016 | Mar. 21, 2016 | Aug. 04, 2015 | Jun. 24, 2015 | Apr. 20, 2015 | Aug. 07, 2007 | Sep. 30, 2015 | Dec. 31, 2016 | Dec. 30, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Stock Issued During Period, Shares, Conversion of Units | 2,167,420 | 258,236 | ||||||||||||
Stock Issued During Period, Value, Conversion of Convertible Securities | $ 589,371 | $ 64,559 | ||||||||||||
Stock Issued During Period, Shares, Exercise of Warrants | 2,818,271 | |||||||||||||
Stock Issued During Period, Value, Exercise of Warrants | $ 864,009 | |||||||||||||
Capitalization, Equity | [1] | 158,139,714 | ||||||||||||
Preferred Stock, Shares Outstanding | 0 | 0 | ||||||||||||
Employee Stock Option [Member] | ||||||||||||||
Share Based Compensation Arrangement by Share Based Payment Award Fair Value Assumptions Expected Forfeiture Rate | 0.00% | |||||||||||||
The 2007 Equity Incentive Plan [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 300,000 | 40,000 | 1,040,000 | |||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ 0.45 | $ 0.35 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | 120,000 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ 0.46 | $ 0.44 | $ 0.44 | |||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period | 262,500 | 262,500 | ||||||||||||
The 2007 Equity Incentive Plan [Member] | Maximum [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 10 years | |||||||||||||
Outside of the 2007 Plan [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 1,009,718 | 2,075,931 | ||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ 0.48 | $ 0.40 | ||||||||||||
Sharebased Compensation Arrangement by Sharebased Payment Award Options Granted in Period, Fair Value | $ 357,312 | $ 887,864 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ 0.43 | $ 0.40 | $ 0.40 | |||||||||||
Other Liabilities, Current | $ 316,007 | $ 942,509 | ||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value | $ 99,600 | $ 74,145 | ||||||||||||
Outside of the 2007 Plan [Member] | Board of Directors and Vendors [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 1,009,718 | 2,075,934 | ||||||||||||
Outside of the 2007 Plan [Member] | Maximum [Member] | Board of Directors and Vendors [Member] | ||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ 0.83 | $ 0.65 | ||||||||||||
Outside of the 2007 Plan [Member] | Minimum [Member] | Board of Directors and Vendors [Member] | ||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ 0.33 | $ 0.33 | ||||||||||||
Selling, General and Administrative Expenses [Member] | ||||||||||||||
Allocated Share-based Compensation Expense | $ 751,113 | $ 1,831,313 | ||||||||||||
Selling, General and Administrative Expenses [Member] | The 2007 Equity Incentive Plan [Member] | ||||||||||||||
Allocated Share-based Compensation Expense | $ 119,971 | $ 620,403 | $ 76,950 | $ 94,050 | ||||||||||
Consultants [Member] | ||||||||||||||
Stock Issued During Period, Shares, Issued for Services | 2,342,264 | 631,643 | ||||||||||||
Consultants [Member] | Selling, General and Administrative Expenses [Member] | ||||||||||||||
Stock Issued During Period, Value, Issued for Services | $ 993,078 | |||||||||||||
Officers and Consultants [Member] | Accrued and Unpaid Salary and Unreimbursed Expenses [Member] | ||||||||||||||
Stock Issued During Period, Shares, Issued for Services | 1,370,480 | |||||||||||||
Officers and Consultants [Member] | Selling, General and Administrative Expenses [Member] | Accrued and Unpaid Salary and Unreimbursed Expenses [Member] | ||||||||||||||
Stock Issued During Period, Value, Issued for Services | $ 670,339 | |||||||||||||
Non-employee Members of the Board of Directors [Member] | The 2007 Equity Incentive Plan [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 40,000 | 40,000 | ||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ 0.45 | $ 0.38 | ||||||||||||
Non-employee Members of the Board of Directors [Member] | Selling, General and Administrative Expenses [Member] | The 2007 Equity Incentive Plan [Member] | ||||||||||||||
Sharebased Compensation Arrangement by Sharebased Payment Award Options Granted in Period, Fair Value | $ 18,000 | $ 15,200 | ||||||||||||
Board of Directors and Vendors [Member] | The 2007 Equity Incentive Plan [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 307,777 | |||||||||||||
Sharebased Compensation Arrangement By Sharebased Payment Award Options Expiration Period Extension | 5 years | |||||||||||||
Chief Financial Officer [Member] | The 2007 Equity Incentive Plan [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number | 15,000 | |||||||||||||
Chief Financial Officer [Member] | The 2007 Equity Incentive Plan [Member] | Subsequent Event [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 300,000 | |||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ 0.69 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares | 125,000 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Remaining Number of Shares to Vest Each Month | 25,000 | |||||||||||||
Consultants, Vendors, and Employees [Member] | The 2007 Equity Incentive Plan [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 1,772,581 | |||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ 0.30 | |||||||||||||
Sharebased Compensation Arrangement By Sharebased Payment Award Options Expiration Period Extension | 5 years | |||||||||||||
Chief Technical Officer [Member] | The 2007 Equity Incentive Plan [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 200,000 | |||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ 0.575 | |||||||||||||
Chief Technical Officer [Member] | Selling, General and Administrative Expenses [Member] | The 2007 Equity Incentive Plan [Member] | ||||||||||||||
Allocated Share-based Compensation Expense | $ 68,000 | |||||||||||||
A Consultant [Member] | The 2007 Equity Incentive Plan [Member] | ||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 700,000 | |||||||||||||
Sharebased Compensation Arrangement by Sharebased Payment Award Options Granted in Period, Fair Value | $ 238,000 | |||||||||||||
Sharebased Compensation Arrangement By Sharebased Payment Award Options Expiration Period Extension | 10 years | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | $ 0.40 | |||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ 0.34 | |||||||||||||
A Consultant [Member] | Selling, General and Administrative Expenses [Member] | The 2007 Equity Incentive Plan [Member] | ||||||||||||||
Allocated Share-based Compensation Expense | $ 79,280 | $ 79,280 | ||||||||||||
[1] | The total shares issued in the above table of 158,139,714 assumes that all options and warrants are exercised and that all convertible notes are converted to common stock. The total does not take into account future stock issuances related to the payment of interest. |
Note 5 - Stockholders' Equity -
Note 5 - Stockholders' Equity - Total Capitalization (Details) - shares | Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Outstanding Common Stock: (in shares) | 92,975,970 | |||
Outstanding Options: (in shares) | 30,065,352 | |||
Outstanding Warrants: (in shares) | 20,035,114 | 13,779,438 | 8,838,122 | |
Subtotal: (in shares) | 143,076,436 | |||
Shares issuable upon conversion of Convertible Promissory Notes: (in shares) | 15,063,278 | |||
Total (in shares) | [1] | 158,139,714 | ||
[1] | The total shares issued in the above table of 158,139,714 assumes that all options and warrants are exercised and that all convertible notes are converted to common stock. The total does not take into account future stock issuances related to the payment of interest. |
Note 5 - Stockholders' Equity32
Note 5 - Stockholders' Equity - Stock Options Issued Under the 2007 Equity Incentive Plan (Details) - $ / shares | Aug. 31, 2016 | Sep. 30, 2015 | Dec. 31, 2016 | Dec. 31, 2015 |
Options outstanding, ending balance (in shares) | 30,065,352 | |||
The 2007 Equity Incentive Plan [Member] | ||||
Options outstanding, beginning balance (in shares) | 8,601,086 | 10,241,086 | 8,601,086 | |
Shares available, beginning balance (in shares) | 3,398,914 | 1,758,914 | 3,398,914 | |
Weighted average price per share, beginning balance (in dollars per share) | $ 0.44 | $ 0.44 | $ 0.44 | |
Options outstanding, granted (in shares) | 300,000 | 40,000 | 1,040,000 | |
Shares available, granted (in shares) | (300,000) | (40,000) | (1,040,000) | |
Exercise price per share, granted (in dollars per share) | $ 0.45 | |||
Weighted average price per share, granted (in dollars per share) | $ 0.45 | $ 0.35 | ||
Options outstanding, plan classification (in shares) | 600,000 | |||
Shares available, plan classification (in shares) | (600,000) | |||
Weighted average price per share, plan classification (in dollars per share) | $ 0.33 | |||
Options outstanding, ending balance (in shares) | 9,916,586 | 10,241,086 | ||
Shares available, ending balance (in shares) | 1,981,414 | 1,758,914 | ||
Weighted average price per share, ending balance (in dollars per share) | $ 0.46 | $ 0.44 | ||
Options outstanding, exercised (in shares) | (102,000) | |||
Exercise price per share, exercised (in dollars per share) | $ 0.35 | |||
Weighted average price per share, exercised (in dollars per share) | $ 0.35 | |||
Options outstanding, cancelled (in shares) | (262,500) | (262,500) | ||
Shares available, cancelled (in shares) | 262,500 | 262,500 | ||
Exercise price per share, cancelled (in dollars per share) | $ 0.40 | |||
Weighted average price per share, cancelled (in dollars per share) | 0.40 | |||
The 2007 Equity Incentive Plan [Member] | Minimum [Member] | ||||
Exercise price per share, beginning balance (in dollars per share) | $ 0.23 | 0.22 | 0.23 | |
Exercise price per share, granted (in dollars per share) | 0.30 | |||
Exercise price per share, plan classification (in dollars per share) | 0.30 | |||
Exercise price per share, ending balance (in dollars per share) | 0.22 | 0.22 | ||
The 2007 Equity Incentive Plan [Member] | Maximum [Member] | ||||
Exercise price per share, beginning balance (in dollars per share) | $ 1.89 | 1.89 | 1.89 | |
Exercise price per share, granted (in dollars per share) | 0.58 | |||
Exercise price per share, plan classification (in dollars per share) | 0.60 | |||
Exercise price per share, ending balance (in dollars per share) | $ 1.89 | $ 1.89 |
Note 5 - Stockholders' Equity33
Note 5 - Stockholders' Equity - Stock Options Issued Under the 2007 Equity Incentive Plan by Exercise Price Range (Details) - $ / shares | 12 Months Ended | ||
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Options Outstanding (in shares) | 30,065,352 | ||
The 2007 Equity Incentive Plan [Member] | |||
Options Outstanding (in shares) | 9,916,586 | 10,241,086 | 8,601,086 |
Exercise Price Range, Lower Limit (in dollars per share) | $ 0.22 | ||
Exercise Price Range, Upper Limit (in dollars per share) | $ 1.89 | ||
Weighted Average Remaining Contractual Life (Year) | 5 years | ||
Weighted Average Exercise Price (in dollars per share) | $ 0.46 | ||
Currently Exercisable, Number Of Shares (in shares) | 9,916,586 | ||
Currently Exercisable, Weighted Average Exercise Price (in dollars per share) | $ 0.46 | ||
The 2007 Equity Incentive Plan [Member] | Exercise Price Range 1 [Member] | |||
Options Outstanding (in shares) | 525,000 | ||
Exercise Price Range, Lower Limit (in dollars per share) | $ 0.40 | ||
Exercise Price Range, Upper Limit (in dollars per share) | $ 1.89 | ||
Weighted Average Remaining Contractual Life (Year) | 1 year | ||
Weighted Average Exercise Price (in dollars per share) | $ 1.06 | ||
Currently Exercisable, Number Of Shares (in shares) | 525,000 | ||
Currently Exercisable, Weighted Average Exercise Price (in dollars per share) | $ 1.06 | ||
The 2007 Equity Incentive Plan [Member] | Exercise Price Range 2 [Member] | |||
Options Outstanding (in shares) | 892,135 | ||
Exercise Price Range, Lower Limit (in dollars per share) | $ 0.28 | ||
Exercise Price Range, Upper Limit (in dollars per share) | $ 0.99 | ||
Weighted Average Remaining Contractual Life (Year) | 2 years | ||
Weighted Average Exercise Price (in dollars per share) | $ 0.51 | ||
Currently Exercisable, Number Of Shares (in shares) | 892,135 | ||
Currently Exercisable, Weighted Average Exercise Price (in dollars per share) | $ 0.51 | ||
The 2007 Equity Incentive Plan [Member] | Exercise Price Range 3 [Member] | |||
Options Outstanding (in shares) | 1,020,000 | ||
Exercise Price Range, Lower Limit (in dollars per share) | $ 0.25 | ||
Exercise Price Range, Upper Limit (in dollars per share) | $ 0.70 | ||
Weighted Average Remaining Contractual Life (Year) | 3 years | ||
Weighted Average Exercise Price (in dollars per share) | $ 0.55 | ||
Currently Exercisable, Number Of Shares (in shares) | 1,020,000 | ||
Currently Exercisable, Weighted Average Exercise Price (in dollars per share) | $ 0.55 | ||
The 2007 Equity Incentive Plan [Member] | Exercise Price Range 4 [Member] | |||
Options Outstanding (in shares) | 3,650,528 | ||
Exercise Price Range, Lower Limit (in dollars per share) | $ 0.22 | ||
Exercise Price Range, Upper Limit (in dollars per share) | $ 0.57 | ||
Weighted Average Remaining Contractual Life (Year) | 4 years | ||
Weighted Average Exercise Price (in dollars per share) | $ 0.37 | ||
Currently Exercisable, Number Of Shares (in shares) | 3,650,528 | ||
Currently Exercisable, Weighted Average Exercise Price (in dollars per share) | $ 0.37 | ||
The 2007 Equity Incentive Plan [Member] | Exercise Price Range 5 [Member] | |||
Options Outstanding (in shares) | 1,656,262 | ||
Exercise Price Range, Lower Limit (in dollars per share) | $ 0.34 | ||
Exercise Price Range, Upper Limit (in dollars per share) | $ 0.40 | ||
Weighted Average Remaining Contractual Life (Year) | 5 years | ||
Weighted Average Exercise Price (in dollars per share) | $ 0.36 | ||
Currently Exercisable, Number Of Shares (in shares) | 1,656,262 | ||
Currently Exercisable, Weighted Average Exercise Price (in dollars per share) | $ 0.36 | ||
The 2007 Equity Incentive Plan [Member] | Exercise Price Range 6 [Member] | |||
Options Outstanding (in shares) | 715,161 | ||
Exercise Price Range, Lower Limit (in dollars per share) | $ 0.28 | ||
Exercise Price Range, Upper Limit (in dollars per share) | $ 0.40 | ||
Weighted Average Remaining Contractual Life (Year) | 6 years | ||
Weighted Average Exercise Price (in dollars per share) | $ 0.36 | ||
Currently Exercisable, Number Of Shares (in shares) | 715,161 | ||
Currently Exercisable, Weighted Average Exercise Price (in dollars per share) | $ 0.36 | ||
The 2007 Equity Incentive Plan [Member] | Exercise Price Range 7 [Member] | |||
Options Outstanding (in shares) | 640,000 | ||
Exercise Price Range, Lower Limit (in dollars per share) | $ 0.30 | ||
Exercise Price Range, Upper Limit (in dollars per share) | $ 0.65 | ||
Weighted Average Remaining Contractual Life (Year) | 7 years | ||
Weighted Average Exercise Price (in dollars per share) | $ 0.48 | ||
Currently Exercisable, Number Of Shares (in shares) | 640,000 | ||
Currently Exercisable, Weighted Average Exercise Price (in dollars per share) | $ 0.48 | ||
The 2007 Equity Incentive Plan [Member] | Exercise Price Range 8 [Member] | |||
Options Outstanding (in shares) | 477,500 | ||
Exercise Price Range, Lower Limit (in dollars per share) | $ 0.38 | ||
Exercise Price Range, Upper Limit (in dollars per share) | $ 0.40 | ||
Weighted Average Remaining Contractual Life (Year) | 8 years | ||
Weighted Average Exercise Price (in dollars per share) | $ 0.42 | ||
Currently Exercisable, Number Of Shares (in shares) | 477,500 | ||
Currently Exercisable, Weighted Average Exercise Price (in dollars per share) | $ 0.42 | ||
The 2007 Equity Incentive Plan [Member] | Exercise Price Range 9 [Member] | |||
Options Outstanding (in shares) | 340,000 | ||
Exercise Price Range, Lower Limit (in dollars per share) | $ 0.45 | ||
Exercise Price Range, Upper Limit (in dollars per share) | $ 0.57 | ||
Weighted Average Remaining Contractual Life (Year) | 9 years | ||
Weighted Average Exercise Price (in dollars per share) | $ 0.56 | ||
Currently Exercisable, Number Of Shares (in shares) | 340,000 | ||
Currently Exercisable, Weighted Average Exercise Price (in dollars per share) | $ 0.56 |
Note 5 - Stockholders' Equity34
Note 5 - Stockholders' Equity - Stock Options Issued Outside of the 2007 Equity Incentive Plan (Details) - $ / shares | 12 Months Ended | |
Dec. 31, 2016 | Dec. 31, 2015 | |
Options outstanding, ending balance (in shares) | 30,065,352 | |
Outside of the 2007 Plan [Member] | ||
Options outstanding, beginning balance (in shares) | 19,394,975 | 17,965,291 |
Weighted average price per share, beginning balance (in dollars per share) | $ 0.40 | $ 0.40 |
Options outstanding, granted (in shares) | 1,009,718 | 2,075,931 |
Weighted average price per share, granted (in dollars per share) | $ 0.48 | $ 0.40 |
Options outstanding, expired (in shares) | (46,250) | |
Exercise price per share, expired (in dollars per share) | $ 0.30 | |
Weighted average price per share, expired (in dollars per share) | $ 0.30 | |
Shares available, plan classification (in shares) | (600,000) | |
Weighted average price per share, plan classification (in dollars per share) | $ 0.33 | |
Options outstanding, ending balance (in shares) | 20,148,766 | 19,394,975 |
Weighted average price per share, ending balance (in dollars per share) | $ 0.43 | $ 0.40 |
Options outstanding, exercised (in shares) | (255,927) | |
Exercise price per share, exercised (in dollars per share) | $ 0.25 | |
Weighted average price per share, exercised (in dollars per share) | 0.35 | |
Outside of the 2007 Plan [Member] | Minimum [Member] | ||
Exercise price per share, beginning balance (in dollars per share) | 0.18 | 0.18 |
Exercise price per share, granted (in dollars per share) | 0.33 | 0.25 |
Exercise price per share, plan classification (in dollars per share) | 0.30 | |
Exercise price per share, ending balance (in dollars per share) | 0.18 | 0.18 |
Outside of the 2007 Plan [Member] | Maximum [Member] | ||
Exercise price per share, beginning balance (in dollars per share) | 1 | 1 |
Exercise price per share, granted (in dollars per share) | 0.83 | 0.65 |
Exercise price per share, plan classification (in dollars per share) | 0.63 | |
Exercise price per share, ending balance (in dollars per share) | $ 1 | $ 1 |
Note 5 - Stockholders' Equity35
Note 5 - Stockholders' Equity - Stock Options Issued Outside of the 2007 Equity Incentive Plan by Exercise Price Range (Details) - $ / shares | 12 Months Ended | ||
Dec. 31, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Options Outstanding (in shares) | 30,065,352 | ||
Outside of the 2007 Plan [Member] | |||
Options Outstanding (in shares) | 20,148,766 | 19,394,975 | 17,965,291 |
Weighted Average Remaining Contractual Life (Year) | 4 years | ||
Weighted Average Exercise Price (in dollars per share) | $ 0.40 | ||
Currently Exercisable, Number Of Shares (in shares) | 19,998,766 | ||
Currently Exercisable, Weighted Average Exercise Price (in dollars per share) | $ 0.40 | ||
Exercise Price Range, Lower Limit (in dollars per share) | 0.18 | ||
Exercise Price Range, Upper Limit (in dollars per share) | $ 1 | ||
Outside of the 2007 Plan [Member] | Exercise Price Range 1 [Member] | |||
Options Outstanding (in shares) | 7,733,259 | ||
Weighted Average Remaining Contractual Life (Year) | 91 days | ||
Weighted Average Exercise Price (in dollars per share) | $ 0.18 | ||
Currently Exercisable, Number Of Shares (in shares) | 7,733,259 | ||
Currently Exercisable, Weighted Average Exercise Price (in dollars per share) | $ 0.18 | ||
Outside of the 2007 Plan [Member] | Exercise Price Range 2 [Member] | |||
Options Outstanding (in shares) | 2,400,000 | ||
Weighted Average Remaining Contractual Life (Year) | 91 days | ||
Weighted Average Exercise Price (in dollars per share) | $ 0.99 | ||
Currently Exercisable, Number Of Shares (in shares) | 2,400,000 | ||
Currently Exercisable, Weighted Average Exercise Price (in dollars per share) | $ 0.99 | ||
Outside of the 2007 Plan [Member] | Exercise Price Range 3 [Member] | |||
Options Outstanding (in shares) | 691,975 | ||
Weighted Average Remaining Contractual Life (Year) | 2 years | ||
Weighted Average Exercise Price (in dollars per share) | $ 0.55 | ||
Currently Exercisable, Number Of Shares (in shares) | 691,975 | ||
Currently Exercisable, Weighted Average Exercise Price (in dollars per share) | $ 0.55 | ||
Outside of the 2007 Plan [Member] | Exercise Price Range 4 [Member] | |||
Options Outstanding (in shares) | 800,000 | ||
Weighted Average Remaining Contractual Life (Year) | 5 years | ||
Weighted Average Exercise Price (in dollars per share) | $ 1 | ||
Currently Exercisable, Number Of Shares (in shares) | 800,000 | ||
Currently Exercisable, Weighted Average Exercise Price (in dollars per share) | $ 1 | ||
Outside of the 2007 Plan [Member] | Exercise Price Range 5 [Member] | |||
Options Outstanding (in shares) | 168,750 | ||
Weighted Average Remaining Contractual Life (Year) | 6 years | ||
Weighted Average Exercise Price (in dollars per share) | $ 0.40 | ||
Currently Exercisable, Number Of Shares (in shares) | 168,750 | ||
Currently Exercisable, Weighted Average Exercise Price (in dollars per share) | $ 0.40 | ||
Outside of the 2007 Plan [Member] | Exercise Price Range 6 [Member] | |||
Options Outstanding (in shares) | 1,497,986 | ||
Weighted Average Remaining Contractual Life (Year) | 6 years | ||
Weighted Average Exercise Price (in dollars per share) | $ 0.30 | ||
Currently Exercisable, Number Of Shares (in shares) | 1,497,986 | ||
Currently Exercisable, Weighted Average Exercise Price (in dollars per share) | $ 0.30 | ||
Outside of the 2007 Plan [Member] | Exercise Price Range 7 [Member] | |||
Options Outstanding (in shares) | 3,122,093 | ||
Weighted Average Remaining Contractual Life (Year) | 7 years | ||
Weighted Average Exercise Price (in dollars per share) | $ 0.32 | ||
Currently Exercisable, Number Of Shares (in shares) | 3,122,093 | ||
Currently Exercisable, Weighted Average Exercise Price (in dollars per share) | $ 0.32 | ||
Exercise Price Range, Lower Limit (in dollars per share) | 0.25 | ||
Exercise Price Range, Upper Limit (in dollars per share) | $ 0.65 | ||
Outside of the 2007 Plan [Member] | Exercise Price Range 8 [Member] | |||
Options Outstanding (in shares) | 2,120,947 | ||
Weighted Average Remaining Contractual Life (Year) | 8 years | ||
Weighted Average Exercise Price (in dollars per share) | $ 0.37 | ||
Currently Exercisable, Number Of Shares (in shares) | 2,120,947 | ||
Currently Exercisable, Weighted Average Exercise Price (in dollars per share) | $ 0.37 | ||
Exercise Price Range, Lower Limit (in dollars per share) | 0.33 | ||
Exercise Price Range, Upper Limit (in dollars per share) | $ 0.47 | ||
Outside of the 2007 Plan [Member] | Exercise Price Range 9 [Member] | |||
Options Outstanding (in shares) | 1,388,166 | ||
Weighted Average Remaining Contractual Life (Year) | 9 years | ||
Weighted Average Exercise Price (in dollars per share) | $ 0.47 | ||
Currently Exercisable, Number Of Shares (in shares) | 1,238,116 | ||
Currently Exercisable, Weighted Average Exercise Price (in dollars per share) | $ 0.47 | ||
Exercise Price Range, Lower Limit (in dollars per share) | 0.33 | ||
Exercise Price Range, Upper Limit (in dollars per share) | $ 0.65 | ||
Outside of the 2007 Plan [Member] | Exercise Price Range 10 [Member] | |||
Options Outstanding (in shares) | 225,641 | ||
Weighted Average Remaining Contractual Life (Year) | 10 years | ||
Weighted Average Exercise Price (in dollars per share) | $ 0.76 | ||
Currently Exercisable, Number Of Shares (in shares) | 225,641 | ||
Currently Exercisable, Weighted Average Exercise Price (in dollars per share) | $ 0.76 | ||
Exercise Price Range, Lower Limit (in dollars per share) | 0.60 | ||
Exercise Price Range, Upper Limit (in dollars per share) | $ 0.83 |
Note 5 - Stockholders' Equity36
Note 5 - Stockholders' Equity - Stock Options, Valuation Assumptions (Details) | 12 Months Ended | |
Dec. 31, 2016 | Dec. 31, 2015 | |
Non Plan [Member] | ||
Life in years (Year) | 7 years | 7 years |
Non Plan [Member] | Minimum [Member] | ||
Risk free interest rate | 1.91% | 1.83% |
Expected volatility | 623.00% | 794.00% |
Non Plan [Member] | Maximum [Member] | ||
Risk free interest rate | 2.49% | 2.33% |
Expected volatility | 738.00% | 821.00% |
The 2007 Equity Incentive Plan [Member] | ||
Life in years (Year) | 5 years | |
The 2007 Equity Incentive Plan [Member] | Minimum [Member] | ||
Risk free interest rate | 1.36% | 1.60% |
Expected volatility | 315.00% | 322.00% |
Life in years (Year) | 3 years | |
The 2007 Equity Incentive Plan [Member] | Maximum [Member] | ||
Risk free interest rate | 2.14% | 2.38% |
Expected volatility | 794.00% | 807.00% |
Life in years (Year) | 7 years |
Note 6 - Warrants (Details Text
Note 6 - Warrants (Details Textual) - USD ($) | 12 Months Ended | |||||||
Dec. 31, 2016 | Dec. 30, 2016 | Dec. 28, 2016 | Dec. 27, 2016 | Sep. 17, 2016 | Jul. 08, 2016 | Dec. 31, 2015 | Dec. 31, 2014 | |
Class of Warrant or Right, Outstanding | 20,035,114 | 13,779,438 | 8,838,122 | |||||
Winter 2016 Unit Offering [Member] | ||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 292,983 | 292,983 | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.70 | $ 0.70 | ||||||
Discount On Convertible Note Payable | $ 167,000 | |||||||
Series A Warrant [Member] | ||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 5,429,872 | 9,597,123 | ||||||
Discount On Convertible Note Payable | $ 2,115,874 | $ 3,319,906 | ||||||
Series A Warrants, Exercise Price 1 [Member] | ||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 2,814,286 | 6,320,800 | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.45 | $ 0.40 | ||||||
Series A Warrants, Exercise Price 2 [Member] | ||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 2,615,586 | 3,276,323 | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.70 | $ 0.45 | ||||||
Series A Warrants Expiring June 1, 2020 [Member] | ||||||||
Class of Warrant or Right, Outstanding | 4,059,744 | |||||||
Series A Warrants Expiring July 31, 2021 [Member] | ||||||||
Class of Warrant or Right, Outstanding | 854,545 | |||||||
Warrants Issued Concurrently with Line of Credit [Member] | ||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 300,000 | |||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.35 | |||||||
Debt Instrument, Unamortized Discount | $ 237,405 | |||||||
Warrant Issued in Exchange of Cancelled Line of Credit [Member] | ||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 515,583 | 515,583 | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.70 | $ 0.70 | ||||||
Discount On Convertible Note Payable | $ 283,571 | |||||||
Debt Conversion, Original Debt, Amount | $ 283,571 | |||||||
Warrants Issued Concurrently With One Year Convertible Note [Member] | ||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 400,000 | 400,000 | ||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.75 | $ 0.65 | ||||||
Discount On Convertible Note Payable | $ 280,000 | $ 160,000 | ||||||
Debt Instrument, Unamortized Discount | $ 120,000 | |||||||
Conversion of Notes Payable [Member] | ||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 266,000 | |||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 0.30 | |||||||
Discount On Convertible Note Payable | $ 133,000 |
Note 6 - Warrants - Warrants Ou
Note 6 - Warrants - Warrants Outstanding (Details) - $ / shares | 12 Months Ended | |
Dec. 31, 2016 | Dec. 31, 2015 | |
Outstanding (in shares) | 13,779,438 | 8,838,122 |
Issued (in shares) | 6,822,855 | 12,693,395 |
Exercised (in shares) | (2,818,271) | |
Expired (in shares) | (2,383,545) | (7,752,079) |
Outstanding (in shares) | 20,035,114 | 13,779,438 |
Prior year extensions (in shares) | 4,634,637 | |
Prior year extensions, price range (in dollars per share) | $ 0.30 | |
Minimum [Member] | ||
Outstanding, price range (in dollars per share) | 0.125 | $ 0.125 |
Issued, price range (in dollars per share) | 0.35 | 0.30 |
Exercised, price range (in dollars per share) | 0.25 | 0.30 |
Expired, price range (in dollars per share) | 0.55 | 0.25 |
Outstanding, price range (in dollars per share) | 0.125 | 0.125 |
Maximum [Member] | ||
Outstanding, price range (in dollars per share) | 1 | 1 |
Issued, price range (in dollars per share) | 0.75 | 0.45 |
Exercised, price range (in dollars per share) | 0.40 | 0.50 |
Expired, price range (in dollars per share) | 0.75 | 0.75 |
Outstanding, price range (in dollars per share) | $ 1 | $ 1 |
Note 6 - Warrants - Assumptions
Note 6 - Warrants - Assumptions Used to Determine Fair Value of Warrants (Details) | 12 Months Ended | |
Dec. 31, 2016 | Dec. 31, 2015 | |
Minimum [Member] | ||
Risk free interest rate | 0.95% | 0.97% |
Expected volatility | 301.00% | 255.00% |
Expected life in years (Year) | 3 years | 3 years |
Maximum [Member] | ||
Risk free interest rate | 1.96% | 1.60% |
Expected volatility | 315.00% | 332.00% |
Expected life in years (Year) | 5 years | 5 years |
Note 7 - Accounts Payable and40
Note 7 - Accounts Payable and Accrued Expenses (Details Textual) - USD ($) | 1 Months Ended | 12 Months Ended | |||
Jan. 31, 2017 | Dec. 31, 2016 | Dec. 31, 2015 | Dec. 30, 2016 | Sep. 27, 2016 | |
Accrued Payroll Taxes, Possible Reduced Amount | $ 5,000 | ||||
Accrued Bonuses, Current | 80,000 | ||||
Share Price | $ 0.83 | ||||
Selling, General and Administrative Expense | $ 3,714,398 | $ 3,551,522 | |||
Chief Executive Officer [Member] | |||||
Accrued Bonuses, Current | $ 60,000 | ||||
Chief Executive Officer [Member] | Subsequent Event [Member] | |||||
Bonuses Paid | $ 40,000 | ||||
Officer [Member] | |||||
Stock Issued During Period, Shares, Issued for Services | 738,837 | ||||
Selling, General and Administrative Expense | $ 309,975 | ||||
Officer [Member] | Minimum [Member] | |||||
Share Price | $ 0.35 | ||||
Officer [Member] | Maximum [Member] | |||||
Share Price | $ 0.36 | ||||
Consultants [Member] | |||||
Stock Issued During Period, Shares, Issued for Services | 2,342,264 | 631,643 | |||
Selling, General and Administrative Expense | $ 993,078 | $ 360,364 | |||
Consultants [Member] | Minimum [Member] | |||||
Share Price | $ 0.25 | $ 0.35 | |||
Consultants [Member] | Maximum [Member] | |||||
Share Price | $ 0.83 | $ 0.36 | |||
Chief Science Officer [Member] | |||||
Accrued Bonuses, Current | $ 60,000 |
Note 7 - Accounts Payable and41
Note 7 - Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Details) - USD ($) | Dec. 31, 2016 | Dec. 31, 2015 |
Accounts payable | $ 22,231 | $ 174,539 |
Payroll tax liability | 137,500 | 137,500 |
Officer bonus | 80,000 | |
Accrued interest | 40,372 | 12,944 |
Total Accounts Payable and Accrued Expenses | $ 280,103 | $ 324,983 |
Note 8 - Provision for Income42
Note 8 - Provision for Income Taxes (Details Textual) $ in Millions | 12 Months Ended |
Dec. 31, 2016USD ($) | |
Operating Loss Carryforwards | $ 45 |
Valuation Allowance Percentage | 100.00% |
Note 9 - Noncontrolling Inter43
Note 9 - Noncontrolling Interest (Details Textual) - USD ($) | Dec. 30, 2015 | Dec. 17, 2012 | Dec. 31, 2016 | Dec. 31, 2015 |
Proceeds from Issuance or Sale of Equity | $ 750,000 | |||
Consulting Services, Monthly Payment | $ 23,438 | |||
Consulting Services, Period of Services | 4 years | |||
Net Income (Loss) Attributable to Noncontrolling Interest | (234,604) | (21,054) | ||
Clyra Medical Technology Inc [Member] | ||||
Sale of Stock, Percentage of Ownership after Transaction | 54.00% | |||
Clyra Medical Technology Inc [Member] | ||||
Investment Owned, Balance, Shares | 7,500 | |||
Preferred Stock, Dividend Rate, Percentage | 8.00% | |||
Preferred Shares Dividend, Period | 5 years | |||
Dividends Payable | 60,000 | |||
Net Income (Loss) Attributable to Noncontrolling Interest | $ 508,414 | $ 115,859 | ||
Clyra Medical Technology Inc [Member] | Series A Preferred Stock [Member] | Sanatio [Member] | ||||
Sale of Stock, Number of Shares Issued in Transaction | 9,830 | |||
Proceeds from Issuance or Sale of Equity | $ 750,000 | |||
Clyra Medical Technology Inc [Member] | Each of 3 Individuals [Member] | ||||
Stock Issued During Period, Shares, New Issues | 1,500 | |||
Sanatio [Member] | Clyra Medical Technology Inc [Member] | ||||
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners | 40.00% |
Note 10 - Subsequent Events (De
Note 10 - Subsequent Events (Details Textual) - USD ($) | Jan. 13, 2017 | Dec. 30, 2016 | Jul. 08, 2016 | Mar. 31, 2017 | Sep. 30, 2015 |
Debt Instrument, Convertible, Conversion Price | $ 0.25 | ||||
One Year Convertible Notes [Member] | |||||
Proceeds from Convertible Debt | $ 250,000 | $ 250,000 | |||
Debt Instrument, Interest Rate, Stated Percentage | 3.00% | 3.00% | |||
Debt Instrument, Convertible, Conversion Price | $ 0.57 | $ 0.45 | |||
Subsequent Event [Member] | One Year Convertible Notes [Member] | |||||
Debt Conversion, Original Debt, Amount | $ 280,000 | ||||
Debt Conversion, Converted Instrument, Shares Issued | 640,889 | ||||
Unit Offering [Member] | Scenario, Forecast [Member] | |||||
Proceeds from Convertible Debt | $ 125,000 | ||||
Debt Instrument, Interest Rate, Stated Percentage | 12.00% | ||||
Debt Instrument, Convertible, Conversion Price | $ 0.70 | ||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 219,298 |